General Information of This Antigen
Antigen ID
TAR0TXGBY
Antigen Name
Vascular endothelial growth factor receptor 2 (KDR)
Gene Name
KDR
Gene ID
3791
Synonym
FLK1; VEGFR2; Fetal liver kinase 1;Kinase insert domain receptor;Protein-tyrosine kinase receptor flk-1;CD_antigen=CD309
Sequence
MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLD
WLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQD
YRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWD
SKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGE
KLVLNC.TELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQ
GLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEI
KWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQ
IGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPC
EEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERV
ISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPV
CKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVL
ERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNL
TIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWLLL
VIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPLGR
GAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVNLL
GACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLKRR
LDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLASR
KCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVY
TIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTMLDC
WHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVSCM
EEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDSGM
VLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYSSE
EAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV

    Click to Show/Hide
Family
Tyr protein family
Function
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

    Click to Show/Hide
Uniprot Entry
VGFR2_HUMAN
HGNC ID
HGNC:6307
KEGG ID
hsa:3791
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
Anti-VEGF antibody
ADC Info ADC Name Payload Target Linker Ref
YL242
YL0010014
DNA topoisomerase 1 (TOP1)
VK*G-NHCH2-O linker
[1]
Anti-VEGFR-2 nanobody
ADC Info ADC Name Payload Target Linker Ref
VGRNb-DT
Diphtheria toxin
Eukaryotic elongation factor 2 kinase (EEF2K)
Sulfo-SMCC
[2]
Ramucirumab
ADC Info ADC Name Payload Target Linker Ref
Ramucirumab-IR700 conjugate
IRDye 700DX
Undisclosed
Undisclosed
[3]
2-DG/aV-siCPT1C
siCPT1C
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
[4]
Undisclosed
ADC Info ADC Name Payload Target Linker Ref
SAB-Y18
Undisclosed
Undisclosed
Undisclosed
[5]
VEGFR2 monoclonal antibody-drug conjugate
Undisclosed
Undisclosed
Undisclosed
[6]
V-DOS47
Undisclosed
Undisclosed
Undisclosed
[7]
References
Ref 1 Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors
Ref 2 Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line. Mol Biotechnol. 2022 Nov;64(11):1218-1226. doi: 10.1007/s12033-022-00485-1. Epub 2022 Apr 27.
Ref 3 Vascular endothelial growth factor receptor 2 targeted photoimmunotherapy. Cancer Research. 2018 ;78(13):-. doi: 10.1158/1538-7445.AM2018-5767.
Ref 4 Cascade-Responsive 2-DG Nanocapsules Encapsulate aV-siCPT1C Conjugates to Inhibit Glioblastoma through Multiple Inhibition of Energy Metabolism. ACS Appl Mater Interfaces. 2023 Mar 1;15(8):10356-10370. doi: 10.1021/acsami.2c19285. Epub 2023 Feb 14.
Ref 5 Introduction to basic information on ADC drug SAB-Y18.
Ref 6 Sorrento next-generation cancer therapeutics; 2014
Ref 7 DOS47-a broad anti-cancer therapeutic platform; 2020